Please assess the completion status of the following clinical trial:

Trial Title: Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed well differentiated or moderately differentiated neuroendocrine tumor from either a primary or metastatic site~* Must have disease that is not amenable to curative resection~* Must have evidence of disease progression within 12 months prior to study entry~* Must have measurable disease (RECIST 1.1)~* Prior chemoembolization of local ablative therapies are allowed, provided there is measurable disease outside of the area treated, or documented evidence of progression at the site of prior treatment~* No limit to number of prior treatments. Prior bevacizumab allowed unless discontinued due to unacceptable toxicity. Prior TKI targeting VEGF receptors allowed~* Treatment with a somatostatin analog required for all subjects~* Subjects with history of hypertension must be adequately controlled~* Therapeutic anticoagulation is allowed. Must be on a stable dose of anticoagulant medication~* Must agree to use adequate contraception prior to study entry, for the duration of study participation and for 3 months after last administration of study drug~Exclusion Criteria:~* Prior treatment including chemoembolization within 4 weeks of study entry~* Major surgery within 4 weeks of study entry or minor surgery within 2 weeks of study entry~* Pregnant or breastfeeding~* Poorly differentiated carcinoma, high grade neuroendocrine tumor or small cell carcinoma~* Prior treatment with Ziv-aflibercept~* Pancreatic neuroendocrine tumor (islet cell carcinoma)will be excluded from this study. All non functional and functional islet cell carcinomas such as insulinoma, glucagonoma, gastrinoma, VIPoma will be excluded.~* Not adequately recovered from toxicity of previous therapy~* Known untreated brain or other central nervous system metastases~* Known allergy to any of the study agents or to compounds of similar chemical or biologic composition~* History of congestive heart failure~* Symptomatic peripheral arterial disease~* Unhealed wounds, ulcers or bone fractures~* HIV positive or active Hepatitis infection~* History of abdominal fistula, GI perforation, intra abdominal abscess, uncontrolled GI bleeding, diverticulitis within 6 months of study entry~* History of arterial thrombotic events such as myocardial infarction, unstable angina pectoris or any ischemic or hemorrhagic cerebrovascular accident within the past 6 months~* No history of pulmonary embolism, DVT or vascular access related thrombosis if not also receiving adequate anticoagulation at a stable dose.~* No history of prior or synchronous malignancy except if treated with curative intent at least 3 years prior to study entry, or adequately treated non-melanoma skin cancer, cervical carcinoma in situ, or prostate intraepithelial neoplasia without evidence of prostate cancer~* Uncontrolled non-malignant illness that may increase the risks associated with study participation or may interfere with the conduct of the study or interpretation of study results~* Uncontrolled psychiatric illness or social situations that would limit compliance with study requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental Treatment Arm (Type: EXPERIMENTAL): Ziv-aflibercept IV every 2 weeks, 4 mg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete